Phathom Pharmaceuticals, Inc. (PHAT)
- Previous Close
4.2900 - Open
4.0000 - Bid 3.2400 x 100
- Ask 3.4300 x 1900
- Day's Range
3.0701 - 4.0000 - 52 Week Range
3.0700 - 19.7100 - Volume
5,480,029 - Avg. Volume
1,267,358 - Market Cap (intraday)
234.018M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-5.1800 - Earnings Date May 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.00
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
www.phathompharma.comRecent News: PHAT
View More
Performance Overview: PHAT
Trailing total returns as of 5/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHAT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHAT
View MoreValuation Measures
Market Cap
234.02M
Enterprise Value
225.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.73
Price/Book (mrq)
--
Enterprise Value/Revenue
2.75
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.78%
Return on Equity (ttm)
--
Revenue (ttm)
55.25M
Net Income Avi to Common (ttm)
-334.33M
Diluted EPS (ttm)
-5.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
297.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-203.85M
Research Analysis: PHAT
View MoreResearch Reports: PHAT
View MoreDaily – Vickers Top Buyers & Sellers for 07/18/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/26/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/12/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/10/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.